Skip to main content
Livermore
Livermore
ZHEN

Rice Hall James & Associates, LLC

SEC CIK
0001230765
Latest filing
Aug 7, 2026

The latest 13F from Rice Hall James & Associates, LLC covers Q2 2026 (filed Aug 7, 2026): 240 long positions worth $2.05B. The top 10 holdings make up 24.1% of the portfolio, and the largest is Ligand Pharmaceuticals Inc (LGND) at 4.2%. Livermore has 23 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
12
Est. +$46.4M
Added
112
Est. +$114.2M
Reduced
101
Est. −$121.4M
Sold out
15
Est. −$41.2M

Top 5 holdings

Share of this quarter's portfolio value

  1. LGNDLigand Pharmaceuticals Inc
    4.2%$85.4MHistory
  2. ACIWAci Worldwide, Inc.
    2.5%$50.6MHistory
  3. ARLOArlo Technologies, Inc.
    2.4%$50.3MHistory
  4. FNFabrinet
    2.4%$49.2MHistory
  5. ESTAEstablishment Labs Holdings Inc.
    2.3%$48.1MHistory

Share of portfolio

Top 5 holdings and the other 235 positions, by share of portfolio value

  1. LGND4.2%
  2. ACIW2.5%
  3. ARLO2.4%
  4. FN2.4%
  5. ESTA2.3%
  6. Other 235 positions86.2%

Biggest buys

New and added positions, by estimated amount bought

  1. OSKOshkosh Corp
    +$16.3MNewHistory
  2. UPWKUpwork, Inc
    +$12.3MAddedHistory
  3. TTITetra Technologies Inc
    +$11.6MAddedHistory
  4. BMRNBiomarin Pharmaceutical Inc
    +$8.21MAddedHistory
  5. PBHPrestige Consumer Healthcare Inc.
    +$7.94MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. OSKOshkosh Corp
    +0.79 pp0.0% → 0.8%History
  2. ESTAEstablishment Labs Holdings Inc.
    +0.61 pp1.7% → 2.3%History
  3. TTITetra Technologies Inc
    +0.57 pp<0.1% → 0.6%History
  4. BMRNBiomarin Pharmaceutical Inc
    +0.36 pp0.3% → 0.7%History
  5. UPWKUpwork, Inc
    +0.33 pp0.8% → 1.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. AEHRAehr Test Systems
    −$17.7MReducedHistory
  2. CEVACeva Inc
    −$15.2MReducedHistory
  3. FOLDAmicus Therapeutics, Inc.
    −$11.1MSold outHistory
  4. FNFabrinet
    −$10.3MReducedHistory
  5. GTLSChart Industries Inc
    −$7.34MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. FNFabrinet
    −0.68 pp3.1% → 2.4%History
  2. FOLDAmicus Therapeutics, Inc.
    −0.62 pp0.6% → 0.0%History
  3. DFINDonnelley Financial Solutions, Inc.
    −0.47 pp2.0% → 1.6%History
  4. GTLSChart Industries Inc
    −0.46 pp0.8% → 0.4%History
  5. SLNOSoleno Therapeutics Inc
    −0.38 pp0.4% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$2.05B
+$258.9M (+14.4%) vs. prior quarter
Positions
240
−3 vs. prior quarter
Top 10 concentration
24.1%
Top 10 as share of value
Turnover
8.3%
Q2 2026, one quarter
Average holding period
15.5 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $3.07B (Q1 2021)

Q1 2021: $3.07BQ2 2021: $2.81BQ3 2021: $2.71BQ4 2021: $2.82BQ1 2022: $2.51BQ2 2022: $2.07BQ3 2022: $1.72BQ4 2022: $1.74BQ1 2023: $1.76BQ2 2023: $1.76BQ3 2023: $1.57BQ4 2023: $1.73BQ1 2024: $1.75BQ2 2024: $1.67BQ3 2024: $1.85BQ4 2024: $1.82BQ1 2025: $1.70BQ2 2025: $1.86BQ3 2025: $1.83BQ4 2025: $1.82BQ1 2026: $1.80BQ2 2026: $2.05B
Q1 2021Q2 2026
13F filings of Rice Hall James & Associates, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 7, 2026240$2.05BLGNDACIWARLOvs. Q1 2026SEC
Q1 2026May 15, 2026243$1.80BLGNDFNARLOvs. Q4 2025SEC
Q4 2025Feb 17, 2026243$1.82BLGNDARLOFOLDvs. Q3 2025SEC
Q3 2025Oct 16, 2025248$1.83BARLOACIWLGNDvs. Q2 2025SEC
Q2 2025Aug 11, 2025247$1.86BARLOVRNADFINvs. Q1 2025SEC
Q1 2025May 1, 2025248$1.70BLRNVRNAACIWvs. Q4 2024SEC
Q4 2024Jan 31, 2025249$1.82BLRNDFINTKOvs. Q3 2024SEC
Q3 2024Oct 28, 2024250$1.85BLRNDFINACIWvs. Q2 2024SEC
Q2 2024Aug 7, 2024256$1.67BLRNDFINACIWvs. Q1 2024SEC
Q1 2024Apr 23, 2024257$1.75BLRNDFINDOORvs. Q4 2023SEC
Q4 2023Feb 9, 2024260$1.73BDFINLRNWNS Hldgs Ltdvs. Q3 2023SEC
Q3 2023Nov 2, 2023260$1.57BDFINLRNWNS Hldgs Ltdvs. Q2 2023SEC
Q2 2023Jul 24, 2023262$1.76BWWEDOORWNS Hldgs Ltdvs. Q1 2023SEC
Q1 2023May 12, 2023262$1.76BWNS Hldgs LtdWWEEEFTvs. Q4 2022SEC
Q4 2022Jan 27, 2023260$1.74BWNS Hldgs LtdDFINDOORvs. Q3 2022SEC
Q3 2022Nov 1, 2022265$1.72BWNS Hldgs LtdLRNDFINvs. Q2 2022SEC
Q2 2022Aug 8, 2022265$2.07BWNS Hldgs LtdLRNMEDvs. Q1 2022SEC
Q1 2022May 26, 2022Amended306$2.51BWNS Hldgs LtdEEFTACIWvs. Q4 2021SEC
Q4 2021Feb 14, 2022312$2.82BWNS Hldgs LtdDOORZDvs. Q3 2021SEC
Q3 2021Nov 9, 2021309$2.71BZDWNS Hldgs LtdDOORvs. Q2 2021SEC
Q2 2021Jul 29, 2021313$2.81BZDMEDDOORvs. Q1 2021SEC
Q1 2021May 14, 2021315$3.07BZDDOORWNS Hldgs Ltd–SEC

13D and 13G filings

Companies where Rice Hall James & Associates, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Rice Hall James & Associates, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
CNTYCentury Casinos Inc13G5.06%1.49M shares+0.14 ppfrom 4.92%Feb 16, 20216 filingsJan 9, 2026SEC

Latest filings

16 filings on file made by Rice Hall James & Associates, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Rice Hall James & Associates, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
CNTYCentury Casinos IncJan 9, 20262:50 PM ET13G5.06%1.49M shares+0.14 ppfrom 4.92%Dec 31, 2025SEC
CNTYCentury Casinos IncOct 8, 202512:11 PM ET13G/A4.92%1.48M shares−0.26 ppfrom 5.18%Below 5%Sep 30, 2025SEC
TRAKReposiTrak, Inc.May 1, 20254:48 PM ET13G/A4.67%853.1K shares–Below 5%Mar 31, 2025SEC
CNTYCentury Casinos IncFeb 3, 202512:03 PM ET13G5.18%1.59M shares–Dec 31, 2024SEC
TRAKReposiTrak, Inc.Feb 14, 202413G/AOld format–––SEC
TRAKReposiTrak, Inc.Feb 14, 202313G/AOld format–––SEC
CNTYCentury Casinos IncFeb 14, 202313G/AOld format–––SEC
TRAKReposiTrak, Inc.Feb 14, 202213GOld format–New–SEC
WLDNWilldan Group, Inc.Feb 14, 202213G/AOld format–––SEC
Points.com Inc.Feb 14, 202213G/AOld format–––SEC
CNTYCentury Casinos IncFeb 14, 202213G/AOld format–––SEC
Biospecifics Technologies CorpFeb 16, 20217:50 AM ET13G/AOld format–––SEC
WLDNWilldan Group, Inc.Feb 16, 202113G/AOld format–––SEC
Points International LtdFeb 16, 202113G/AOld format–––SEC
CNTYCentury Casinos IncFeb 16, 202113G/AOld format–––SEC
CEVACeva IncFeb 16, 202113G/AOld format–––SEC